TY - JOUR
AU - Pastorio, Chiara
AU - Richard, Khumoekae
AU - Usmani, Shariq
AU - Kissmann, Ann-Kathrin
AU - Bolotnikov, Grigory
AU - Gosálbez, Guillermo
AU - Hayn, Manuel
AU - Koepke, Lennart
AU - Sauertnik, Alina
AU - Preising, Andrea
AU - Preising, Nico
AU - Ständker, Ludger
AU - Fair, Matthew
AU - Morris, Jessicamarie
AU - Papasavvas, Emmanouil
AU - Liu, Qin
AU - Sun, Honghong
AU - Rodríguez, Armando
AU - Mounzer, Karam
AU - Wiese, Sebastian
AU - Tebas, Pablo
AU - Du, Yangzhu
AU - Laird, Gregory M
AU - Jaritz, Markus
AU - Rosenau, Frank
AU - Gaidt, Moritz M
AU - Sparrer, Konstantin M J
AU - Montaner, Luis J
AU - Kirchhoff, Frank
TI - Retinol Binding Protein 4 reactivates latent HIV-1 by triggering canonical NF-κB, JAK/STAT5 and JNK signalling.
JO - Signal transduction and targeted therapy
VL - 10
IS - 1
SN - 2095-9907
CY - London
PB - Macmillan Publishers, part of Springer Nature
M1 - DZNE-2025-01140
SP - 326
PY - 2025
AB - Reactivation of the latent viral reservoirs is crucial for a cure of HIV/AIDS. However, current latency reversing agents are inefficient, and the endogenous factors that have the potential to reactivate HIV in vivo remain poorly understood. To identify natural activators of latent HIV-1, we screened a comprehensive peptide/protein library derived from human hemofiltrate, representing the entire blood peptidome, using J-Lat cell lines harboring transcriptionally silent HIV-1 GFP reporter viruses. Fractions potently reactivating HIV-1 from latency contained human Retinol Binding Protein 4 (RBP4), the carrier of retinol (Vitamin A). We found that retinol-bound holo-RBP4 but not retinol-free apo-RBP4 strongly reactivates HIV-1 in a variety of latently infected T cell lines. Functional analyses indicate that this reactivation involves activation of the canonical NF-κB pathway and is strengthened by JAK/STAT5 and JNK signalling but does not require retinoic acid production. High levels of RBP4 were detected in plasma from both healthy individuals and people living with HIV-1. Physiological concentrations of RBP4 induced significant viral reactivation in latently infected cells from individuals on long-term antiretroviral therapy with undetectable viral loads. As a potent natural HIV-1 latency-reversing agent, RBP4 offers a novel approach to activating the latent reservoirs and bringing us closer to a cure.
KW - Humans
KW - HIV-1: genetics
KW - HIV-1: pathogenicity
KW - NF-kappa B: genetics
KW - Virus Latency: genetics
KW - HIV Infections: genetics
KW - HIV Infections: virology
KW - Retinol-Binding Proteins, Plasma: genetics
KW - Retinol-Binding Proteins, Plasma: metabolism
KW - Virus Activation: genetics
KW - STAT5 Transcription Factor: genetics
KW - Janus Kinases: genetics
KW - MAP Kinase Signaling System: genetics
KW - NF-kappa B (NLM Chemicals)
KW - Retinol-Binding Proteins, Plasma (NLM Chemicals)
KW - RBP4 protein, human (NLM Chemicals)
KW - STAT5 Transcription Factor (NLM Chemicals)
KW - Janus Kinases (NLM Chemicals)
LB - PUB:(DE-HGF)16
C6 - pmid:41038866
C2 - pmc:PMC12491451
DO - DOI:10.1038/s41392-025-02424-3
UR - https://pub.dzne.de/record/281522
ER -